“Autoimmune Diseases and B Cell Immunity” Featuring Dr. Mark Shlomchik
On this episode of the Immunology Podcast, Dr. Mark Shlomchik talks about the role of toll-like receptors in lupus and how his autoimmune disease research led to potential cancer therapies.
Dr. Mark Shlomchik is a Professor and Chair of Immunology at the University of Pittsburgh. He is also the Founder and Chief Scientific Officer of BlueSphere Bio, a company working to create individualized T cell therapies. He talks about the role of toll-like receptors in lupus, how his autoimmune disease research led to potential cancer therapies, and starting a biotech company with his brother.
Join us while we explore the B(ad) side of B cells in autoimmunity, with Dr. Shlomchik!
Dr. Brenda Raud, host
Find more episodes at immunologypodcast.com or wherever you get your podcasts.
This Episode's Immunology Roundup:
- Antibody Escape in Omicron Subvariants – Researchers showed that the BA.4 and BA.5 SARS-CoV-2 sub-lineages contain mutations that reduce neutralization from vaccines and previous infection.
- Long COVID in the Brain – After mild respiratory COVID, mice displayed elevated CSF cytokines, impaired hippocampal neurogenesis, decreased oligodendrocytes, and myelin loss.
- Pregnancy and Intracellular Infection – Pregnancy-induced post-translational antibody modification enables protection against the prototypical intracellular pathogen Listeria monocytogenes.
- Sex-Specific Immune Responses to Tumors – Scientists demonstrated that sex-related differences in tumor burden depend on adaptive immunity.
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer